Pulmocide presented five posters at the recent 7th Advances Against Aspergillosis Conference in Manchester, and the meeting organisers published a Press Release about the work Pulmocide presented, stating:

“Dr Kazuhiro Ito from Pulmocide, working with researchers at Nihon University, Chiba, Japan, demonstrated that inhaled PC945 was highly effective in early therapy of life-threatening invasive aspergillosis in mice. The compound is a novel azole with activity about 100-fold more against Aspergillus fumigatus than voriconazole, the leading treatment currently. PC945 also reduced inflammation in the lung. PC945 represents the first of a new generation of inhaled antifungals, primarily for fungal asthma, cystic fibrosis and prevention of invasive aspergillosis. Clinical studies of aerosolized PC945 are likely to commence in early 2017.”

A full copy of the press release can be downloaded here:
Download

The 5 posters are as follows:

In vitro anti-fungal profile of a novel and long acting azole, PC945
PC945 is a novel antifungal agent designed for inhalation treatment, and in clinical development for the treatment of aspergillosis. In this study, in vitro activity of PC945 was investigated versus Aspergillus fumigatus (A. fumigatus) and a range of pathogenic yeasts and moulds.
Download

Activity of PC945, a novel and long acting azole, against clinical Aspergillus fumigatus isolates from France and the United Kingdom
PC945 is a novel antifungal agent being developed as an inhalation therapy for the treatment of aspergillosis. In this study the antifungal activity of PC945 was assessed by performing susceptibility testing against clinical isolates of Aspergillus fumigatus (A.fumigatus) in France and the United Kingdom.
Download

In vitro and in vivo anti-fungal activity of PC945, a novel azole, on azole sensitive and resistant Aspergillus fumigatus strains as a topical monotherapy or in combination with oral posaconazole
PC945 is a novel antifungal agent being developed as an inhalation therapy for the treatment of aspergillosis. This study examined the activity of PC945 on azole sensitive and resistant Aspergillus fumigatus (A. fumigatus) strains as a topical monotherapy or combined with posaconazole in vitro using a model of human alveoli and in vivo using A. fumigatus-infected immunocompromised mice.
Download

In vivo Efficacy of Intranasally Dosed PC945, a novel antifungal agent, in Aspergillus fumigatus infection in immunocompromised mice
PC945 is a novel antifungal agent developed as an inhalation therapy for the treatment of invasive aspergillosis. In this study, we examined the effects of intranasally dosed PC945 on biomarkers and survival rates in Aspergillus fumigatus infected immunocompromised mice.
(This abstract was also selected for oral presentation)
Download

Anti-fungal activity of PC1244, a novel azole, on azole sensitive and resistant Aspergillus fumigatus strains and other fungi
PC1244 is a novel antifungal agent designed for inhalation treatment of invasive aspergillosis or difficult fungi. In this study, the in vitro profile of PC1244 was investigated against Aspergillus fumigatus (A. fumigatus) and a range of yeasts and moulds.
Download